Ipamorelin · research summary

Growth hormone (GH) hypersecretion and GH receptor resistance in streptozotocin diabetic mice in response to a GH secretagogue.

Experimental diabesity research · 2003. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Experimental study comparing GH and IGF-I axis responses in STZ diabetic and nondiabetic mice following ipamorelin or saline injection.
“The growth hormone (GH) and insulin-like growth factor I (IGF-I) axis were studied in streptozotocin (STZ) diabetic and nondiabetic female mice following intravenous (IV) injection of the GH secretagogue (GHS) ipamorelin or saline.”

Subjects

Adult female Balb/C(a) mice, divided into diabetic and nondiabetic groups.
“Four groups of adult female Balb/C(a) mice (Bomholtgaard, Ry, Denmark), with initial body weights of 15 to 19 g, were studied.”

Sample size

7 to 10 mice per group.
“Note. Values are means SEM, n = 7-10 per group.”

Duration

14 days from diabetes induction to sample collection.
“On day 14, blood samples were obtained before and 10 minutes after the injection.”

Reported findings

Serum GH levels were significantly higher in diabetic mice than in nondiabetic mice following ipamorelin stimulation.
“Following ipamorelin injection, the GH levels were found to be 150 ± 35 μg/L and 62 ± 11 μg/L in the diabetic compared to the nondiabetic mice (P < .05).”
Serum IGF-I levels were lower in diabetic animals and did not increase after stimulation, whereas they rose in nondiabetic animals.
“Serum IGF-I levels were lower in diabetic than in nondiabetic animals, and rose after stimulation only in the nondiabetic animals.”
Hepatic GH resistance and IGF-I mRNA and peptide levels increased in nondiabetic animals after stimulation but remained unaffected in diabetic mice.
“Furthermore, hepatic GH resistance and IGF-I mRNA levels and IGF-I peptide were increased in nondiabetic animals in response to GH stimulation, whereas the low levels per se of all these parameters in diabetic mice were unaffected.”

Source: PubMed 14630569 · DOI 10.1155/EDR.2003.73 · all study summaries

Study type

Experimental study comparing GH and IGF-I axis responses in STZ diabetic and nondiabetic mice following ipamorelin or saline injection.

“The growth hormone (GH) and insulin-like growth factor I (IGF-I) axis were studied in streptozotocin (STZ) diabetic and nondiabetic female mice following intravenous (IV) injection of the GH secretagogue (GHS) ipamorelin or saline.”

Reported findings

Serum GH levels were significantly higher in diabetic mice than in nondiabetic mice following ipamorelin stimulation.

“Following ipamorelin injection, the GH levels were found to be 150 ± 35 μg/L and 62 ± 11 μg/L in the diabetic compared to the nondiabetic mice (P < .05).”

Serum IGF-I levels were lower in diabetic animals and did not increase after stimulation, whereas they rose in nondiabetic animals.

“Serum IGF-I levels were lower in diabetic than in nondiabetic animals, and rose after stimulation only in the nondiabetic animals.”

Hepatic GH resistance and IGF-I mRNA and peptide levels increased in nondiabetic animals after stimulation but remained unaffected in diabetic mice.

“Furthermore, hepatic GH resistance and IGF-I mRNA levels and IGF-I peptide were increased in nondiabetic animals in response to GH stimulation, whereas the low levels per se of all these parameters in diabetic mice were unaffected.”